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BiogenesisWith the extraordinary progress of mitochondrial science and cell biology, novel biochemical pathways have
emerged as strategic points of bioenergetic regulation and control. They include mitochondrial fusion, ﬁssion
and organellar motility along microtubules and microﬁlaments (mitochondrial dynamics), mitochondrial
turnover (biogenesis and degradation), andmitochondrial phospholipids synthesis. Yet,much is still unknown
about the mutual interaction between mitochondrial energy state, biogenesis, dynamics and degradation.
Meanwhile, clinical research into metabolic abnormalities in tumors as diverse as renal carcinoma, glio-
blastomas, paragangliomas or skin leiomyomata, has designated new genes, oncogenes and oncometabolites
involved in the regulation of cellular and mitochondrial energy production. Furthermore, the examination
of rare neurological diseases such as Charcot-Marie Tooth type 2a, Autosomal Dominant Optic Atrophy,
Lethal Defect of Mitochondrial and Peroxisomal Fission, or Spastic Paraplegia suggested involvement of
MFN2, OPA1/3, DRP1 or Paraplegin, in the auxiliary control of mitochondrial energy production. Lastly,
advances in the understanding ofmitochondrial apoptosis have suggested a supplementary role for Bcl2 or Bax
in the regulation ofmitochondrial respiration anddynamics,which has fostered the investigation of alternative
mechanisms of energy regulation. In this review, we discuss the regulatory mechanisms of cellular and
mitochondrial energy production, andwe emphasize the importance of the study of rare neurological diseases
in addition to more common disorders such as cancer, for the fundamental understanding of cellular and
mitochondrial energy production.gie mitochondriale, Université
076 Bordeaux Cedex, France.
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In this review article, we discuss the established and potential
pathways that control mitochondrial energetics. First, we summarize
the ﬁndings obtained on isolated mitochondria using metabolic con-
trol analysis, which helped us to understand the multi-step control of
mitochondrial energy production (Section 2). Then, we present the
main pathway coordinating cell activity, nutrient availability and
the regulation of energy transduction processes (Section 3), and we
further compile the molecular regulatory mechanisms of mitochon-
drial respiratory chain (Section 4). In Section 5, we describe the
hypothesis of regulating mitochondrial energy production by organ-
elle shape changes, while the hypothesis of controlling mitochondrial
dynamics by the mitochondrial energy state is discussed in Section 6.
In Section 7, we present the retrograde pathways involved in the
adaptation of the cellular global processes of energy production to
changes in mitochondrial activity. Lastly, we discuss the link between
mitochondrial energetics and organelle turnover (Section 8), and wereview the recent developments in medical research that revealed
the importance of mitochondrial bioenergetics and dynamics in the
pathophysiology of cancer and rare neurological disorders (Section 9).
2. Metabolic control analysis of mitochondrial ATP production
The main pathways of cellular energy production described in
mammalian cells are illustrated in Fig. 1. Brieﬂy, nutrients such as
glucose, amino acids and fatty acids are transformed by intermediary
metabolism into their reduced equivalents (NADH, H+ or FADH2),
which are further oxidized by the mitochondrion to generate adeno-
sine triphosphate (ATP). Large amounts of ATP are used in muscle
contraction, nerve impulse conduction, compound biosynthesis or
other biological processes. Mitochondria of normal tissues typically
oxidize combinations of these energy substrates (fatty acids, the
glycolysis end product pyruvate and amino acids) to establish the
electrochemical gradient of protons (ΔµH+) used by the F1Fo–ATP
synthase to produce ATP. The large number of biochemical reactions
engaged in energy transduction initially raised the question of
whether a single rate-limiting step could control the overall process
of energy production [1]. Pioneering studies of metabolic control
analysis (MCA) in the late 1970 s explained that the control of cellular
energy ﬂuxes is shared between all the enzymes of the metabolic
Fig. 1. Overview of the cellular energy metabolic pathways. Glucose enters the cells through speciﬁc transporters and becomes phosphorylated by hexokinase into G6P, then cleaved
in 2 molecules of glyceraldehyde 3 phosphate, dephosphorylated by pyruvate kinase in the presence of ADP, yielding pyruvate; these overall reactions produce 2 ATP and are
commonly grouped under the term of glycolysis (anaerobic and cytosolic), in contrast to respiration (aerobic andmitochondrial). Pyruvate can be transformed into lactate due to the
excess of NADH + H+ resulting from poor respiration, or enters mitochondria to be oxydatively decarboxylated in the presence of coenzymes which will fuel the respiratory chain
with oxygen to yield ATP, H2O and CO2. Oxydative decarboxylations include the reactions of the Krebs cycle, and the β-oxidation (Lynen's helix) which provides essentially acyl-CoA
then acetyl-CoA for the tricarboxylic cycle together with NAD(P)H + H+ and FADH + H+, and CO2. Mitochondria contain other enzymes involved in catabolism (urea cycle) and
synthesis of amino acids and of uridine with the dihydroorotase using FADH + H+. They also play a pivotal role by the phosphorylation of nucleotides, notably thymidine. The
mitochondrial respiratory chain consists of four enzyme complexes (complexes I–IV), and two mobile carriers (coenzyme Q and cytochrome c) along which the electrons liberated
by the oxidation of NADH and FADH2 are passed, and ultimately transferred to molecular oxygen. This respiratory process generates the electrochemical gradient of protons used by
the F1–Fo ATP synthase (i.e., complex V) to phosphorylate ADP and produce ATP.
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rylation). These enzymatic steps include the transport of energy me-
tabolites (e.g., pyruvate carrier), substrate oxidation (e.g., pyruvate
dehydrogenase complex) and ATP synthesis (e.g., mitochondrial com-
plex V). At this time, the steps of mitochondrial fusion and ﬁssion
were not considered for MCA, as most studies were performed on
isolated mitochondria and because mitochondrial dynamics had not
yet emerged. The possible control of mitochondrial fusion and ﬁssion
on the respiratory ﬂux remains underinvestigated, and the ﬁssion
inhibitor mdivi-1 could permit the evaluation of the control co-
efﬁcient of mitochondrial ﬁssion on oxygen consumption.
Deciphering the control of a metabolic pathway requires the iden-
tiﬁcation of all the enzymatic steps involved in the ﬂux and the
quantiﬁcation of the importance of each of these steps in determin-
ing this ﬂux. To do so, one can experimentally measure how the ﬂux
varies when a single enzyme velocity is changed, either by inhibi-
tion or activation, as typically occurs in vivo by regulatory events
(i.e., phosphorylation or conformational changes of complex I). MCA
can be used to answer the following question: how does a reduction
of complex I speciﬁc activity (VI) impact the overall ﬂux of oxygen
consumption (JO2)? In this case, the control of mitochondrial respi-
ration (JO2) by complex I activity (vI), at steady-state, can be mea-
sured by the control coefﬁcient CIJO2≈ (dj/j)/(dv/v)≈ Δ JO2/ ΔvI for
small (inﬁnitesimal) variations of vI. Additionally, the application of
MCA to the oxidative phosphorylation (OXPHOS) network helped to
provide a quantitative picture of OXPHOS control [2–5]. The mainresults of this approach were that (i) the control of mitochondrial
respiration is shared between all of the OXPHOS complexes (no rate
limiting step, per se), (ii) the importance of the control exercised by a
particular enzyme on the respiratory ﬂux is measured by the control
coefﬁcient and (iii) the distribution of control between the different
complexes depends on steady-state respiration. In a previous study
[5], we determined the control coefﬁcients of seven OXPHOS com-
plexes on the oxygen-consumption ﬂux (at state 3) in rat mitochon-
dria isolated from ﬁve different tissues under identical experimental
conditions. The results revealed two groups of tissues: (i) the muscle
and the heart, controlled essentially at the level of the respiratory
chain; and (ii) the liver, the kidney and the brain, controlled mainly
at the level of phosphorylation by ATP synthase and the phosphate
carrier. The possible differences in mitochondrial fusion and ﬁssion
between mitochondria taken from different tissues could contribute
to the variable distribution of OXPHOS control, and more studies on
intact or permeabilized cells are needed to clarify this point.
These differences in the control of oxidative phosphorylation also
reﬂect the physiological variations in the OXPHOS machinery that
adapt the efﬁciency and rate of ATP production to the tissue-speciﬁc
energy demand. According to the metabolic control theory [6,7], the
level of control of a given isolated step on the global ﬂux depends on
several parameters, including the absolute content of enzyme, its
intrinsic kinetic parameters and associated regulations, the architec-
ture of the metabolic network, the concentration of intermediate
substrates and the respective steady-state [8]. To verify this
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OXPHOS metabolic pathway in mitochondria isolated from ﬁve rat
tissues [9]. The results showed that in mammalian tissues, the capa-
city for OXPHOS is highly variable and depends on the combination
of mitochondrial content and the amount and intrinsic activity of
their respiratory chain complexes. These ﬁndings suggest that tissue-
speciﬁc regulation of mitochondrial bioenergetics occurs and that this
regulation could be linked to the highly specialized functions of the
different organs, their variable energy demands as well as their pre-
ferences in the type of energy substrates utilized [10,11]. Accordingly,
a better understanding of the regulation of mitochondrial energy pro-
duction in organs could come from the comparative analysis of the
mitochondrial proteome in different tissues. It is estimated, based on
different studies performed in human heart [12] mouse [13] or rat
[14], that mitochondria contain around 600–700 identiﬁed proteins.
The most recent release of the mitochondrial proteome database
(http://www.mitoproteome.org/) includes 847 protein records. Yet,
a protein correlation proﬁling study suggested that only 63–66% of
these proteins could be assigned to the mitochondrion [15]. The pro-
teomic study by Forner et al. [14] compared mitochondria isolated
from rat muscle, heart and liver, and it revealed that one-third of the
proteins identiﬁed in the soluble fractions are predominantly asso-
ciated with one of the three tissues; it also revealed that a small
percentage of the mitochondrial proteome is unique to each tissue.
Likewise, the possible tissue-speciﬁc expression proﬁle of proteins
involved in mitochondrial dynamics could be investigated by such
proteomic analyses. A study by Aijaz S. et al. identiﬁed important
differences in the expression of OPA1 in nine different human adult
tissues, including the cerebellum, spinal cord, retina, heart, liver and
lung [16]. Differences in the expression levels of Mfn1 and Mfn2 were
also identiﬁed between human tissues with higher expression in the
heart [17] that also contain themitochondriawith the highestOXPHOSFig. 2. Convergent regulation of cellular energy metabolism by the AMP-activated protein kin
demand, the energy supply, and the capacity of the energy transformation systems. Th
metabolism and mitochondrial oxidative phosphorylation perform the efﬁcient transformat
biological processes as diverse as muscle contraction or propagation of the nerve impulse. Th
AMP produced from ADP. In situations of high energy demand (low ATP/ADP), the adenylat
initiate cascades of phosphorylation and stimulates the expression of genes involved in ATP p
AMPK can also stimulate the activity of the sirtuin 1 (sirt 1), which further stimulates the ecapacity [9]. More recently, a modular control analysis was performed
in rat-contracting skeletal muscle in vivo to describe the control of the
enzymatic steps (modules) of ATP production andATP consumption in
the context of skeletal muscle adaptation to hypoxia [18]. Such in vivo
observations combine top-down control analysis with non-invasive
31P-NMR spectroscopy, which allows active mitochondrial fusion,
ﬁssion and motility to be maintained, as compared to studies per-
formed on isolated mitochondria where the mitochondrial compart-
ment is no longer organized as a network. This methodology could
allow for the measurement of the control coefﬁcient of mitochondrial
fusion and ﬁssion on the ﬂux of ATP production. To conclude, MCA
suggests a shared control ofmitochondrial energy production,which is
consistent with the concept of multi-site regulation of oxidative phos-
phorylation, as discussed below.
3. Central mechanisms regulating cellular energy homeostasis
In mammalian cells, energy homeostasis requires a constant coor-
dination between cell activity, nutrient availability and the regulation
of energy transduction processes. This is obtained via a complex sig-
naling system linking energy and nutrient sensing to cellular effectors
that include kinases and transcription factors. While the intracellular
energy status is mirrored by the respective concentrations of the ade-
nine nucleotides ATP, ADP and AMP (as well as phosphocreatine/
creatine), nutrient availability is reﬂected more by the concentration
of glucose and amino-acids. The S6 kinases (S6Ks) 1 and 2 and the
AMP-activated protein kinases (AMPKs) intervene downstream of
these sensors tomodulate growth rate and energymetabolism [19,20].
The AMP-activated protein kinases are activated by alterations in
the cellular AMP/ATP ratio, which is dictated by the balance be-
tween energy supply (ATP production) and energy demand (ATP
consumption) (Fig. 2). When activated by AMP, the AMPKs initiate aases and Sirt 1. At steady-state, the cellular energy production is dictated by the energy
e metabolic pathways of glycolysis, pentose phosphate oxidative arm, intermediary
ion of nutrients in adenosine triphosphate (ATP), which is ultimately used for essential
e cytosolic ratio of ATP/ADP reﬂects the cellular energy state, as indicated by the level of
e kinase produces AMP which activates the AMP-activated protein kinases (AMPK) that
roduction, while reducing that of genes involved in ATP consumption. Alternatively, the
xpression of genes involved in ATP production.
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produce ATP (glycolysis and oxidative phosphorylation via the stimu-
lation of mitochondrial biogenesis) and to switch-off the anabolic
pathways that consume ATP (protein, fatty acid and cholesterol syn-
thesis). AMPKs target numerous genes involved in lipid, carbohydrate
and protein metabolism, as well as those involved in cell signaling,
transcription and ion transport (for a review see [21]). More recently,
it was discovered in mouse skeletal muscle that AMPKs further regu-
late energy metabolism through the activation of the sirtuin SIRT1
[22,23]. This results in deacetylating and altering the activity of down-
stream SIRT1 targets, including the peroxisome proliferator-activated
receptor-γ coactivator l alpha (PGC1α), forkhead box O1 (FOXO1) and
forkhead box 03 (FOXO3a) transcription factors. The FOXO transcrip-
tion factors are major downstream targets of the PI3K signaling
pathway; they control the transcription of several genes involved in
cell life and death, cell cycle, differentiation, reactive oxygen species
(ROS) detoxiﬁcation, DNA repair [24,25] and particularly the gluco-
neogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate
carboxykinase, which produce glucose in situations of strong energy
demand (as occurs during starvation). Accordingly, the AMPKs can be
activated by cellular stress, exercise, and a wide range of hormones
or pharmaceutical agents that affect cellular energy metabolism (e.g.,
metformin, thiazolidinediones, adiponectin, leptin, ghrelin/cannabi-
noids and resveratrol [26]). In addition to the master control exerted
by the AMPKs and sirtuins, the regulation of cellular energy metab-
olism is also inﬂuenced by calcium and ROS as is discussed below.
4. Molecular regulatory mechanisms of mitochondrial
ATP production
Cellular adaptation to environmental and physiological constraints
necessitates that the control of mitochondrial respiration be ﬁne
tuned in its response to changes in energy demand and substrate
delivery. This is accomplished by regulatory events which modulateFig. 3. Multi-site regulation of mitochondrial oxidative phosphorylation. The modulation of
production to the cellular needs and environmental bioenergetic constraints.OXPHOS, both structurally and functionally. Accordingly, different
tissues exhibit large differences in the composition of the OXPHOS
machinery and in the organization of mitochondria [9], and these
differences could reﬂect their unique physiological activity. In addi-
tion, mitochondria also participate in fundamental cell signaling
and apoptotic processes, the regulation of which might also lead to
changes in organellar content, composition and functionality. Yet,
the regulation of mitochondrial energy production is concerted and
dispersed, as shown in Fig. 3. There are ﬁve different levels of OXPHOS
regulation. (1) The ﬁrst level includes the direct modulation of respi-
ratory chain kinetic parameters via the expression of rapid or slow
isoforms of complex IV [27], the biochemical modulation of complex
IV catalytic activity by the electric membrane potential (ΔΨ) [28,29],
numerous regulations of all electron transfer chain (ETC) complexes
by post-translational modiﬁcations including phosphorylation or
nitrosylation [30,31], which is emphasized by the discovery of active
kinase and phosphorylases that regulate OXPHOS inside the mito-
chondrion [32] (of particular note, a recent study demonstrated the
existence of cyclic AMP produced inside the mitochondrion, which
regulates oxidative phosphorylation via protein kinase A activation
and subsequent COX phosphorylation [33,34]) and binding to cofac-
tors such as ATP or NO, which also changes ETC capacity [35]. Lastly,
the activation of four mitochondrial dehydrogenases (FAD-glycerol
3-phosphate dehydrogenase [36], pyruvate dehydrogenase phos-
phatase [37], NAD-isocitrate dehydrogenase [38] and oxoglutarate
dehydrogenase [39]) by calcium ions is also involved in stimulat-
ing oxidative phosphorylation in mammalian cells by increasing the
amount of NADH supplied to the respiratory chain. In primary cultures
of skeletal myotubes, stimulation with agonists evoking cytosolic and
mitochondrial Ca2+ signals triggers increases in mitochondrial ATP
synthesis [40]. Live-cell imaging studies indicate decreased agonist-
stimulated mitochondrial ATP production in ﬁbroblasts carrying a
complex I deﬁciency [41]. (2) The intrinsic efﬁciency of OXPHOS can be
regulated by changes in the basal proton conductance or the inducedOXPHOS capacity and activity occurs at different levels to adapt mitochondrial energy
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notably linked to oxygen levels [43], or by changes in the channeling
of respiratory chain intermediate substrates (via differences in the
organization and content of supercomplexes [44,45]). (3) OXPHOS
capacity may also depend on the morphological state of the mito-
chondrial compartment (networked or fragmented) in living mam-
malian cells [46], which relies on highly regulated fusion and ﬁssion
events, mitochondrial motility and changes in organellar membrane
lipid composition [47,48] as well as the osmotic phenomena of mito-
chondrial swelling or shrinking [49,50]. Yet, it remains unclear
whether truly functional coupling exists between the mitochondrial
ultrastructure andOXPHOS capacity, orwhether these twoparameters
solely demonstrate parallel changes (see Section 5, below). (4) An
upper level of mitochondrial-energetics regulation consists of the
modulation of mitochondrial biogenesis and degradation, including
the determination of cellular mtDNA content by PGC1α and sirtuins
[23,51,52], the possible regulation of mtDNA transcription by mito-
chondrial translocation of CREB [53] and the bulk degradation or the
targeted degradation of mitochondria (i.e., oxygen-dependent degra-
dation of COX IV-2 by LON [54]) according to the energy state and
subnetwork localization [55]. Recent advances indicate a prominent
role for PINK1 and parkin in the regulation of mitochondrial degra-
dation according to the energy state [56]. (5) Cell biology has revealed
the heterogeneity of mitochondrial function within the cell, such
that energy production can be further regulated in situ by the cellular
and mitochondrial microenvironment, including the availability of
energy substrates (NADH, H+/NAD+, ADP/ATP, oxygen gradients,
glucose and glutamine) and their delivery at the Q-junction [57],
interactions with other organelles (ER, Golgi, plasma membrane)
[58,59], the concerted regulation of OXPHOS with other functions
(apoptosis and calcium signaling) and the impact of various chemicals
(environmental drugs or medicine). Below, we discuss in detail some
of the recently identiﬁed regulatory mechanisms of mitochondrial
dynamics and biogenesis that might play a role in OXPHOS regulation.
5. Hypothetical regulation of mitochondrial ATP production by
mitochondrial dynamics
Theoretical studies on the regulation of oxidative phosphoryla-
tion in skeletal muscle mitochondria suggest that only the direct acti-
vation of all oxidative phosphorylation enzymes by "some cytosolic
factors" is able to account for the large increase in VO2 and ATP turn-
over accompanied by a very moderate increase in ADP concentration
during the rest-to-work transition [60,61]. Yet, recent ﬁndings in
mitochondrial physiology might allow a hypothetical role for mito-
chondrial dynamics in the rapid regulation of OXPHOS output to be
proposed. Indeed, a recent study by J.C. Martinou and colleagues
showed a rapid stress-induced mitochondrial hyperfusion (SIMH),
which is accompanied by an increase in mitochondrial ATP produc-
tion [62]. Yet, a time-course analysis is required to fully understand
whether stressﬁrst causes hyperfusion, whichwould then be followed
by ATP production. According to the authors, the SIMH process was
dependent upon mitochondrial oxidative phosphorylation because it
was blocked in ρo cells that exhibited a normal mitochondrial
membrane potential but were unable to synthesize ATP. The SIMH
was observed in situations of stress, as induced by actinomycin D,
cycloheximide or UV radiation, which also induced a large increase in
the cellular ATP content (220%, 160% and 120% of the untreated
control, respectively). The increase in themitochondrial ATP synthesis
(oligomycin sensitive) rate was less intense (20–40% over a 15 min
measurement). This discrepancy might be explained by the use of
methyl-pyruvate as an energy substrate, as it does not stimulate the
full capacity of OXPHOS as compared to growth media where all the
energy substrates (including glutamine) are available [62]. Therefore,
the increased ATP levels associated with SIMH could be better
attributed to the combined stimulation of OXPHOS and glycolysis aswell as the possible inhibition of ATP-consuming activities. Still, the
mechanisms by which this (hyper)fusion event could initiate an
increase in mitochondrial and glycolytic ATP synthesis remain
unexplained. It may be speculated that mitochondrial fusion could
improve the physical continuity of both the mitochondrial matrix and
mitochondrial membranes (see the discussion on the existence of
subnetworks, below) and, subsequently, ameliorate the propagation
of the ΔΨ and increase the diffusion space for the energy metabolites
(ADP, NADH) as well as increase their potential interaction with
OXPHOS components to promote ATP production throughout the
entire mitochondrial tubule; or it may be speculated that such
conformational changes impact the respirasome organization and
activate signaling cascades which remain to be determined. Likewise,
the overexpression of mitofusin 2 (Mfn2) improves themitochondrial
capacity to produce ATP and stimulate glucose oxidation [63]. This can
be explained by a higher level of fusion of the mitochondrial network
and the stimulation of mitochondrial biogenesis, as Mfn2 plays a role
in both processes [64]. Hence, only a few observations are available
regarding the stimulation of OXPHOS by an increase in mitochondrial
fusion, while numerous reports indicate an impairment of mitochon-
drial respiration in situations of altered fusion or ﬁssion [65].
6. Hypothesis of a control of mitochondrial dynamics by
mitochondrial energy state
Bioenergetic studies indicate that the processes of fusion and
ﬁssion could be inﬂuenced by the cellular energy state [46]. It remains
unclear whether mitochondrial morphological changes could regulate
energy production via changes in the internal diffusion of energy
metabolites, the sequestration and conduction of ΔΨ or possibly
the delivery of newly synthesized ATP to various cellular areas. It was
shown that signiﬁcant changes occur in the ramiﬁcation and inter-
connection of the mitochondrial network when OXPHOS energy pro-
duction is increased by glucose deprivation [66] or reduced by the use
of respiratory chain inhibitors [46], but the molecular mechanisms of
the observedmitochondrial morphological changes remain unknown.
Pioneering studies by the Verkman group analyzed the diffusive
properties of GFP in the mitochondrial matrix using FRAP and time-
resolved anisotropy [67]. They observed a rapid and unrestricted dif-
fusion of solutes in the mitochondrial matrix. In contrast, more recent
studies using photo-activated GFP abrogated the notion of physical
continuity within the entire mitochondrial compartment and sug-
gested the existence of subnetworks [68]. Usingﬂuorescence-recovery
after photobleaching, a study by Collins and colleagues [69] also dem-
onstrated that mitochondria within a cell are not lumenally contin-
uous. Yet, fusion events could allow the mixing of mitochondrial
matrix constituents and promote functional complementation, as pro-
posed by Nakada et al. [70]. The problem of mitochondrial heteroge-
neity was recently discussed by Orian Shirihai's group [71]. Likewise,
it is unclear whether mitochondrial ATP production is identical when
the organelle harbors a networked or fragmented conﬁguration. More
crucially, it has not been clearly demonstrated that mitochondria truly
function as a global integratednetwork to synthesize vital ATP through
the OXPHOS process. A large body of evidence indicates that the
mitochondrial shape is affected by variations in the state of energy
production induced by (i) energy substrates, (ii) pharmaceutical or
genetic inhibition of OXPHOS, (iii) pathological mutations or (iv) the
cell physiological state. These ﬁndings suggest the existence of a reg-
ulatory loop between OXPHOS and mitochondrial dynamics which
remains to be clariﬁed at the molecular level.
A conceivable hypothesis for the bioenergetic control of mito-
chondrial fusion and ﬁssion by the mitochondrial and/or the cellu-
lar energy state arises from the evidence that OPA1, MFN1, MFN2
and DRP1 require GTP to perform their mechanical activity. Jezek P.
and Hlavata L. proposed the hypothesis that GTP formation by the
Krebs cycle followed by GTP extrusion by the adenine nucleotide
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drial fusion [72]. The conversion of ATP to GTP by nucleoside dipho-
sphate kinases (NDP kinases) located either on the surface of the
mitochondrion or in the intermembrane space might also play an
important role in the bioenergetic control of these dynamins. The NDP
kinase D was shown to be associated with the outer and inner mito-
chondrial membranes [73,74] and was not found in the soluble frac-
tions. NDP kinase D and porins are similarly distributed among the
fractions, thus strongly suggesting that, like porins, NDP kinase D is
associated with contact sites between the outer and the inner mem-
brane. This raises the question of whether NDP-kinase D interacts
with DRP1, Fis1P and MFN2. In addition to NDP-kinase D, intra-
mitochondrial NDP kinases were found in pigeons, such as Nm23-H6,
which partially colocalizes with mitochondria [75].
Apart from this possibility, the analysis of the different proteins
involved in mitochondrial fusion or ﬁssion has recently shown post-
translational regulatory mechanisms for DRP1, OPA1, and MFN2 [76–
80] (for review see [81]), which might also interfere with the mod-
ulation of mitochondrial dynamics and the subsequent control of
OXPHOS capacity in response to the cellular energy state and nutrient
availability (Fig. 4). First, DRP1 can be post-translationally modiﬁed
by protein phosphorylation, ubiquitylation, nitrosylation and sumoy-
lation. So far, the impact of these changes on mitochondrial energy
production has not been investigated, and only the effects on DRP1
recruitment to the mitochondrial membrane, DRP1 turnover, ﬁssion
activity and the sensitivity to apoptosis were analyzed [76–79]. The
expression of a mutant dominant negative form of DRP1 in human
cells induces the impairment of OXPHOS with a strong reduction of
ATP synthesis capacity [46]. Evidence for a link between the cell cycle
and mitochondrial dynamics was found in HeLa cells, as the mito-Fig. 4. Regulation of mitochondrial fusion and ﬁssion by phosphorylation, conjugation, expr
DRP1 can be regulated by ubiquitination, phosphorylation or sumoylation. Mitochondrial fus
short forms; this cleavage is stimulated by a loss of mitochondrial electric membrane potent
expression, notably following an increase in energy demand, or through conjugation with Mchondrial network becomes fragmented in the early mitotic phase,
but is fused again in the daughter cells [82,83]. This process depends
on Drp1 phosphorylation by Cdk1/cyclin. In neuronal cell models of
Alzheimer's disease (overexpression of the pathogenic amyloid pep-
tide precursor APP), the observed increase in mitochondrial ﬁssion
was explained by elevated levels of S-nitrosylated Drp1 (SNO-Drp1)
[84]. Likewise, increased levels of SNO-Drp1 were found in brain
samples from AD patients and AD mouse models [84].
Regarding OPA1, it is well documented that a loss of mitochondrial
membrane potential (i.e., uncoupling by CCCP [85]) triggers the cleav-
age of long isoforms of OPA1 to shorter forms and reduces the ability
for mitochondrial fusion [86]. This cleavage can be caused by different
m-AAA proteases, some of which require ATP, and can be controlled
by prohibitins; it remains to be clariﬁed how the proteases and their
regulators interact based on the cellular energy states. For example,
how does the energy state modify their expression level and self-
proteolytic state? Additionally, 8 OPA1 isoforms result from the alter-
nate splicing of 3 exons (Ex4, Ex4b and Ex5b). How does this pattern
of OPA splicing relate to the state of energy production? Also, is there
a speciﬁc OPA1 isoform that ismore closely related to energy changes?
Alternative splicing is an important mechanism in creating protein
diversity and regulating gene expression in a tissue- or developmen-
tal-speciﬁc manner. Interestingly, the activity of the spliceosome
depends on the levels of ATP, since the PRP16 RNA-dependent ATPase
is required for the second catalytic step of pre-mRNA splicing [87].
The downregulation of OPA1 expression in human cells, as along
with the occurrence of pathogenic mutations in this protein, is asso-
ciated with altered OXPHOS function [88–90]. In the case of Mfn2,
Zorzano A. and colleagues demonstrated that the overproduction
of Mfn2 stimulates OXPHOS activity and mitochondrial biogenesis asession, sumoylation or ubiquitination. The activity of the mitochondrial ﬁssion protein
ion is controlled by the proteolytic cleavage of the OPA protein, which exists as large or
ial, as occurs during energy crisis. The fusion protein Mfn2 is regulated at the level of its
ARCHV.
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expression is induced in situations of increased energy demand, as it
occurs during exercise or exposure to cold temperatures. This would
suggest that a controlled increase in the fusion of the mitochondrial
compartment might stimulate OXPHOS, as observed in SIMH [62].
Mfn2 can also be conjugated with MARCH5 [76,79] to stimulate its
fusion activity. Recent observations also describe a role for MFN2 in
controlling the exchange of ATP/ADP, possibly through protein–
protein interactions, which might offer an additional mechanism by
which mitochondrial fusion could control mitochondrial energy
production [93]. Lastly, Mfn2 was recently identiﬁed at the interface
between the endoplasmic reticulum and the mitochondrion with a
possible role in the regulation of mitochondrial Ca2+ uptake [59]. Yet,
matricial calcium can stimulate different mitochondrial dehy-
drogenases and transporters, which participate in energy production,
such that Mfn2 might also participate in the regulation of mito-
chondrial energetics via calcium signaling. The hypothesis of a role for
OPA1, DRP1 and MFN2 in the regulation of mitochondrial and cellular
energy production is emphasized by the discovery of diseases caused
by mutations in these proteins (see Section 8, below).
The possible interactions between mitochondrial dynamics and
energy production described above could provide an opportunity for
the discovery of drugs that target mitochondrial fusion or ﬁssion
with a stimulatory effect on energy metabolism, to the beneﬁt of
patients suffering from obesity, diabetes and mitochondrial/neuro-
muscular diseases [92,94,95]. New insights into the critical relation-
ships between mitochondrial dynamics and programmed cell death
have demonstrated that Bax and Bak interact with Mfn2 [96], which
might suggest that Bcl-2 family members may also regulate apoptosis
through organelle morphogenesis machineries. Interestingly, Bcl2 can
also directly regulate mitochondrial respiration through the modula-
tion of cytochrome c oxidase (COX) activity [97,98] such that a closerFig. 5. Mitochondria feedbacks. The mitochondrial energy state can retro-regulate the nuc
(2) reactive oxygen species signaling, (3) calcium signaling, (4) the AMPK pathway , and
followed by changes in "energy-state messengers" which include reactive oxygen species (s
GTP, AMP, cAMP, ΔΨ and ΔpH.link between mitochondrial energetics and apoptosis could emerge
in the coming years. Similarly, Furt F. and Moreau P. proposed that
mitochondrial fusion and ﬁssion are lipid-assisted processes such that
changes in mitochondrial membrane homeostasis and lipid compo-
sition could impact organellar dynamics and further inﬂuence energy
metabolism [48]. Similarly, in a study by Choi et al. [47], mitochondrial
phospholipase D (MitoPLD) was shown to migrate to the external
face of mitochondria and to promote trans-mitochondrial membrane
adherence in anMfn-dependent manner by hydrolyzing cardiolipin to
generate phosphatidic acid.
To conclude, awide range of physiological activitiesmutually affect
mitochondrial dynamics, and a directed issue was recently devoted to
this wide-ranging topic [99].
7. Mitochondria-to-nucleus retrograde bioenergetic signaling
When considering the mechanisms regulating mitochondrial
energy production, the existence of feedback mechanisms must be
examined (Fig. 5). This possibility in particular was investigated by
Arnould T. and colleagues, who demonstrated that perturbations of
the mitochondrial energy state can initiate the reverse-regulation
of the global processes of cellular energy metabolism. For instance,
analysis of cultured human cells in which OXPHOS was altered by the
speciﬁc inhibition of respiratory chain complex III or by the suppres-
sion of mitochondrial protein synthesis [100] revealed the activation
of the cAMP-response element binding protein (CREB) with subse-
quent effects on lipid metabolism. A similar retrograde pathway was
activated in response to mitochondrial DNA depletion [101]. These
authors further proposed that CREB-1 is involved in the regulation
of genes encoding mitochondrial proteins during myogenesis and
probably also in other situations of enhanced mitochondrial biogen-
esis [102]. Yet, it remains unclear how the modulation of PGC1-αlear-encoded energy genes, by ﬁve main pathways: (1) energy metabolite signaling,
(5) the sirtuin pathway. The changes in mitochondrial respiratory chain activity are
uch as the diffusive H2O2), mitochondrial and cytosolic calcium, NADH/NAD, ATP/ADP,
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communication. Alternatively, the activation of CREB was shown
to induce the expression of endothelial nitric oxide synthase (eNOS)
[103], and intracellular nitric oxide (NO) generation stimulates mito-
chondrial biogenesis [104–106]. Thus, a molecular cascade includ-
ing CREB, eNOS, NO and PGC1-α could participate in adjusting
the mitochondrial content in situations of altered energy production
(Fig. 5). Accordingly, the increase in mitochondrial content observed
in oncocytic thyroid tumors was associated with the upregulation of
PGC1-α and the generation of NO [107]. Anothermechanism bywhich
the mitochondrial energy state imparts feedback regulation on
OXPHOS was recently proposed by Acin-Perez R. [34], where soluble
adenilyl-cyclase (Mito-SAC) plays a determinant role in the generation
of cyclic AMP (cAMP) (produced from the OXPHOS-synthesized ATP)
inside the mitochondrion, which activates the mitochondrial protein
kinase A (PKA), and triggers the reversible phosphorylation of mito-
chondrial proteins. In this study, the authors used isolated mitochon-
dria to demonstrate that stimulation of PKA with 8Br-cAMP produced
a small but signiﬁcant increase in respiration with glutamate/malate
(12%) and TMPD/ascorbate (13%) and a larger increase in ATP levels
(60–75%). The use of PKA inhibitors considerably reduced these ef-
fects. The identiﬁed targets of PKA involved in the regulation of
OXPHOS were the phosphorylated subunits COXI and COXIV-2. The
proposed biochemical regulation of this "Mito-SAC signaling pathway"
involves the activation of Mito-SAC by bicarbonate, possibly derived
by the carbon dioxide (CO2) generated from the Krebs cycle. TheMito-
SAC is directly regulated by bicarbonate ions (HCO3−), the concen-
tration of which reﬂects the cellular (or mitochondrial) levels of CO2.
The energy-generating metabolic processes (which increase intra-
cellular CO2) can therefore activate the bicarbonate-responsive sAC.
According to Zippin et al. [108], this direct link between metabolic
activity, sAC and cAMP could represent an evolutionarily conserved
mechanism of metabolic feedback regulation.
Lastly, mitochondria can also generate feedback signals via metab-
olites in the cytosol, such as ATP/ADP, ROS, Ca2+ or NADH/NAD,
which participate in the regulation of energy production. The
regulation of cellular energy metabolism by the ATP/ADP ratio is
discussed in the above section on AMP-activated protein kinases.
Regarding the ROS, it was shown that PGC1-α and β (the master
regulators of mitochondrial biogenesis) are stimulated by exogenous
H2O2 (1 mM) [109], an ROS also produced by the mitochondrion. Yet,
the high concentration of H2O2 used in that study could be questioned
with regard to the physiological relevance of these observations.
In a recent study performed in yeast, it was demonstrated that
the mitochondrial generation of ROS leads to the reduction of mito-
chondrial biogenesis via the activation of the HAP2/3/4 and 5 tran-
scription factors [110]. It was also shown that ROS and NO [111], or
their derivatives (reactive nitrogen species, RNS), inhibit mitochon-
drial complex I and could therefore participate in the self-modulation
of ETC activity by the ROS it generates. Complex I activity is regulated
by the cAMP cascade and by the oxygen free radical balance which
makes it "a regulable and vulnerable pacemaker in mitochondrial
respiratory function" according to Papa S. [112]. Recently, it was also
reported that energy metabolism affects cell-death mechanisms via
the generation of ROS and activation of the RIP3 kinase [113]. A key
role of the transcription factor HIF was shown in OXPHOS regulation,
via ROS feedback signaling. The stabilization of the HIF-alpha subunit
by H2O2 was associated with the reduction of respiratory chain sub-
unit levels in renal cancer cells [114]. A complex interplay between
the ROS generated by the mitochondrion and those subsequently
produced by the cytosolic NADPH oxidases (NOXs) could participate
in the signaling cascade by which H2O2 triggers the expression of
metabolic genes [115].
Concerning calcium, it is well documented that numerous mito-
chondrial dehydrogenases and substrate transporters, together with
the post-translational modiﬁcation of F1-FO-ATPase and cytochromeoxidase, are activated by calcium. It was proposed that Ca2+ is an ideal
feed-forward signal for priming ATP production in the heart (see the
recent review by Balaban R.S [116]). Using a metabolic control anal-
ysis (top-down approach), it was demonstrated that Ca2+ activates
both mitochondrial ADP phosphorylation and respiratory chain sub-
strate oxidation to different levels (78% compared to 45%, respec-
tively) to achieve the homeostasis of the mitochondrial membrane
potential [117]. The mitochondrial respiratory chain activity is linked
to changes in the cytosolic ratios of NADH/NAD and pyruvate/lactate,
as the different energy states produce variations in the redox state
of the cytosol; this is further associated with a large number of reg-
ulators. For instance, the sirtuins, which are recently discovered
NAD+-dependent deacetylases, can deacetylate transcription factors
such as FOXOs, p53, and nuclear factor Kappa B (NFΚB), which in
turn participate in the regulation of glucose metabolism. Interest-
ingly, SIRT3, SIRT4, and SIRT5 are localized at the mitochondria, and
their interaction with oxidative phosphorylation has recently been
deciphered. Sirt3 can physically interact with complex I 39-kDa pro-
tein (NDUFA9) and deacetylate this subunit to promote complex
I activity and OXPHOS [118]. Functional studies demonstrate that
mitochondria from Sirt3−/− animals display a selective inhibition of
Complex I activity. Sirt4 inhibits glutamate dehydrogenase [119] and
reduces the synthesis of ATP from mitochondrial glutaminolysis.
Sirt5 was found to co-localize with cytochrome c in the mitochondrial
intermembrane space (IMS) [120,121] and to promote the reversible
acetylation of cytochrome c, thereby affecting its function in respi-
ration or apoptosis.
8. Interaction between mitochondrial energetics and
organelle turnover
The complexity of mitochondrial degradation and its contribution
to the regulation of organelle homeostasis are receiving increasing
attention. Mitochondrial degradation involves the elimination of lipid
membranes and proteins as well as DNA molecules. It has been pro-
posed that mitochondrial degradation is performed by the general
vacuolar/lysosomal autophagy. Autophagy is a bulk pathway used
under diverse stress stimuli for the degradation of various cytosolic
components [122]. The autophagic program includes an increase in
macroautophagic activity and the ensuing degradation of cellular
components. The macroautophagic process starts with the seques-
tration of a cellular component by a double membrane. The
autophagosome resulting from the closure of this membrane sub-
sequently fuses with lysosomes to form an autophagolysosome. The
biological material is eliminated by hydrolytic enzymes at an acidic
pH. The process of mitochondria-speciﬁc autophagy, termed mito-
phagy, is less understood. Recently, a few studies have shown in
various mutant models that mitophagy is partially under the control
of autophagy related genes (ATG5 and 11) [123]. Other components
of the autophagic machineries seem not to be involved in the delivery
of mitochondria to vacuoles/lysosomes [124,125]. Some evidence
has established a link between Bcl2-family members and mitophagy.
Speciﬁcally, Bcl2 and Bcl-xl appear to sequester beclin1 and conse-
quently restrain mitochondrial degradation [126,127]. Altogether,
these results demonstrate that mitophagy is only partially dependent
upon the canonical autophagy pathway, and might implicate mito-
chondrial speciﬁc mechanisms. Recently, several groups investigating
the importance of mitochondrial shape have suggested that mito-
chondrial dynamics selectively regulate mitochondrial degradation
[55]. Shirihai O. and colleagues proposed that the fragmentation of
the mitochondrial network is speciﬁcally targeted at the depolarized
mitochondrial segments. Accordingly, impairing the bioenergetic
function of mitochondria triggers mitophagy [128,129]. These obser-
vations describe mitophagy as a quality-control system that allows
the degradation of non-functional mitochondria. Other studies pro-
pose the same idea of quality control of damaged mitochondria. For
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ing damaged mitochondria [130], senescent keratinocytes also show
increased mitophagic process [131], and cells treated with parkinson
neurotoxin (MPP+) initiate mitophagy [132]. In these studies, the
signal for mitochondrial degradation and the mechanism promot-
ing mitochondrial sorting are not clear. In other words, what is the
mechanism that selects the mitochondrial segments that are to be
degraded, and how are mitochondria segregated for degradation in
this “survey?” Some studies have shown the importance of the mito-
chondrial membrane potential in this mechanism [55,56,133,134].
ROS that alter mitochondria are also implicated in this mechanism
[135]. Additional clues have been identiﬁed through the involvement
of proteins such as the ubiquitin ligase parkin [134]. Recent ﬁndings
by Youle R.J. and colleagues show that parkin is selectively recruited
from the cytosol and taken to damaged mitochondria to trigger their
autophagy. PINK1-accumulation on mitochondria is both necessary
and sufﬁcient to recruit parkin to the mitochondria [56].
Modiﬁcation of proteins by ubiquitination or other types of con-
jugationmight tagmitochondria for degradation [136]. Ubiquitination
is known to be involved in vesicular body sorting through the cytosol
[137]. Moreover, ubiquitination has already been shown both to tag
mitochondrial degradation in sperm and eggs [138] and to control
mitochondria inheritance and morphology in yeast [139]. However
in somatic cells, it is not yet proven that mitochondrial degradation
by autophagy involves ubiquitination. The mitochondrial dynamic
machinery is implicated inmitophagy, and recent evidence has shown
that ubiquitination of DRP1 is a regulator of protein trafﬁcking [76].
These types of modiﬁcations may be used to regulate this machinery
in the control of mitophagy. To date, however, this system, or the pos-
sible involvement of lipids or lipid modiﬁcation, in these processes
has barely been evaluated.
9. Mitochondrial physiology: learning from cancer and
neurological diseases
Recent developments in cancer research have shed light on the
importance of mitochondria for the regulation of tumor gene expres-
sion, via the production of oncometabolites [140], the synthesis of
citrate [141,142], or the signaling by ROS [143] (for review see [144]).
Indeed, tumorigenic mutations in mitochondrial respiratory chain
complex II [140,145] or in the Krebs cycle isocitrate dehydrogenase
(IDH1, IDH2) [146–148] exposed a novel mechanism of pseudo-hypoxic
signaling by which energy metabolites feed-back control the hypoxia
inducible factor (HIF-α), and initiate a transcriptional modulation of
the balance between glycolysis and oxidative phosphorylation [81].
Likewise, genetic studies in tumors revealed the key role of the PDH
kinases (PDK1 and PDK4) for the regulation of oxidative versus non-
oxidative catabolism of glucose [149], of the pyruvate kinase-M2
isoform in the control of serine and phospholipid synthesis [150,151],
of c-Myc for the stimulation of mitochondrial glutaminolysis [152],
and of Oct-1 for the overall control of energy production [153]. The
bioenergetic remodelling of cancer cells and the consequences for
metabolic signaling were reviewed recently in [144]. Accordingly, the
multi-step carcinogenesis process and the associated changes in
tumor microenvironment could suggest the occurrence of successive
waves of metabolic remodelling, with step-by-step differences in the
control of energy production.
The understanding of OXPHOS regulation by mitochondrial dy-
namics will certainly beneﬁt from studies on the pathophysiological
mechanisms of rare neurological disorders caused by mutations in
proteins involved in mitochondrial fusion, ﬁssion, motility or degra-
dation. The more documented mitochondrial dynamic disorders are
the autosomal dominant optic atrophies (ADOA) caused by mutations
in the OPA1 fusion protein [154]. Bioenergetic analyses of OPA1 from
patient's skin ﬁbroblasts revealed the uncoupling of OXPHOS [89]
but the molecular mechanisms underlying this defect remain to beelucidated. Another neuropathy, the Charcot-Marie-Tooth type 2a
disease, can be caused by mutation in the ﬁssion protein Mfn2 which
lead to the reduction of mitochondrial membrane potential and
OXPHOS decoupling [155]. The pathophysiological mechanisms still
remain unresolved, but the recent evidence of a link between Mfn2
and ANT [93] underscores the bioenergetic importance of this protein.
Likewise, the study of spastic paraplegia caused by mutations in
different mitochondrial proteins such as paraplegin [156] could per-
mit to unravel novel mechanisms of OXPHOS regulation.
10. Conclusion
The progress in mitochondrial research has recently emphasized
the importance of mitochondrial fusion and ﬁssion in the modulation
of cell physiological processes, as crucial as apoptosis, calcium sig-
naling, cell division or organ development. The ﬁeld of mitochondrial
bioenergetics is examining the possible regulation of mitochondrial
ATP production by organellar dynamics and motility, in concert with
the regulation of other mitochondrial functions including cell death
execution. Furthermore, it has become more evident that mito-
chondria communicate with the nucleus by signals which might also
depend on the dynamics of themitochondrial compartment, as shown
for calcium.
Thus, it is undoubtful that the knowledge on mitochondrial oxida-
tive phosphorylation, in physiology and pathology, will beneﬁt from
the fundamental analysis of mitochondrial dynamics and turnover.
The possible interaction betweenmitochondrial dynamics and energy
production could also offer an opportunity for the discovery of drugs
that target mitochondrial fusion or ﬁssion with a stimulatory effect on
energy metabolism, to the beneﬁt of patients suffering from obesity,
diabetes and mitochondrial/neuromuscular diseases.
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